Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low-and middle-income countries(LMICs).However,a gulf between paying markets and the endemicity of such ...Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low-and middle-income countries(LMICs).However,a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs.While the pharmaceutical industry views emerging economies as potential new markets,most of the world’s poorest bottom billion now reside in middle-income countries-a fact that has complicated tiered access arrangements.However,product development partnerships-particularly those involving academic institutions and small firms-find commercial opportunities in pursuing even neglected diseases;and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation.Such innovation will be shaped by 1)access to building blocks of knowledge;2)strategic use of intellectual property and innovative financing to meet public health goals;3)collaborative norms of open innovation;and 4)alternative business models,some with a double bottom line.Facing such resource constraints,LMICs are poised to develop a new,more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.展开更多
文摘Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low-and middle-income countries(LMICs).However,a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs.While the pharmaceutical industry views emerging economies as potential new markets,most of the world’s poorest bottom billion now reside in middle-income countries-a fact that has complicated tiered access arrangements.However,product development partnerships-particularly those involving academic institutions and small firms-find commercial opportunities in pursuing even neglected diseases;and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation.Such innovation will be shaped by 1)access to building blocks of knowledge;2)strategic use of intellectual property and innovative financing to meet public health goals;3)collaborative norms of open innovation;and 4)alternative business models,some with a double bottom line.Facing such resource constraints,LMICs are poised to develop a new,more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.
